| Literature DB >> 28324874 |
Carmelo Grasso1, Sergio Buccheri, Davide Capodanno, Antonio Popolo Rubbio, Maria Elena Di Salvo, Salvatore Scandura, Sarah Mangiafico, Tatiana Salerno, Stefano Cannata, Veronica Dezio, Giuseppe Castania, Marco Barbanti, Piera Capranzano, Corrado Tamburino.
Abstract
Percutaneous mitral valve repair (PMVR) with the MitraClip system (Abbott Vascular, Santa Clara, CA, USA) is a valid therapeutic option for patients with severe mitral regurgitation (MR) deemed to be at high or prohibitive surgical risk. Despite the reassuring data on efficacy and long-term durability of the procedure, the proportion of patients with residual or relapsing severe MR after MitraClip therapy is not negligible. In light of the detrimental prognostic impact of severe MR, repeat interventions are increasingly performed in clinical practice using different techniques. In high-risk settings, percutaneous procedures have proven to be effective and safe at reducing MR. Building on this, we sought to summarize the current landscape and clinical experience of reinterventions after failed MitraClip therapy, so as to assist physicians facing the clinical hurdle of proper treatment management after failed PMVR.Entities:
Keywords: Mitral regurgitation; Percutaneous mitral valve repair; Repeat interventions
Mesh:
Year: 2017 PMID: 28324874 DOI: 10.1159/000460240
Source DB: PubMed Journal: Cardiology ISSN: 0008-6312 Impact factor: 1.869